FRANK SANTOS: Open Payments
NPI 1811941651 · WEST NEW YORK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$569 in 35 payments from 8 companies in 2025. Trend: 2023 $265 · 2024 $237 · 2025 $569
Food & beverage: $569
| Company | Payments | Amount |
|---|---|---|
| Almatica Pharma LLC | 11 | $138 |
| Neurocrine BioSciences, Inc. | 6 | $117 |
| Janssen Pharmaceuticals, Inc | 6 | $97 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $85 |
| Teva Pharmaceuticals USA, Inc. | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| SANOFI PASTEUR INC. | 1 | $23 |
| ABBVIE INC. | 1 | $17 |
Products named: LOREEV XR, INGREZZA, CAPLYTA, INVEGA SUSTENNA, UZEDY, SPRAVATO, REXULTI, BEYFORTUS.
Industry payments across NJ — which companies pay providers there.
